The 3rd Glioblastoma Drug Development Summit is the only industry led forum for large pharma, biotech and academic KOLs to unite under the common goal of accelerating the practical translation and clinical development of meaningful therapies for the treatment of glioblastoma. Through investigating the clinical implementation of diverse mechanisms of action, including, DNA damage repair, immunotherapy, oncolytic viruses, cholesterol […]

SMi’sTransdermal and Microneedle Delivery 24-25 January 2022 Workshop: 26th January 2022 Virtual Conference: Online Access Only www.transdermal-microneedle-delivery.co.uk/PharmajournalistWL #SMiTransdermal Sponsored by: LTS Lohmann Therapie-Systeme AG and QuadMedicine Co-Chaired by: Sanjiv Sharma, Senior Lecturer in Medical Engineering, Swansea University Tycho Speaker, Director, Drug Delivery and Biomaterials, AbbVie Ltd SMi's inaugural conference: Transdermal and Microneedle delivery will take place on 24th - 25th January […]

Decipher Mechanisms of Action, Understand Clinical Data & Ignite Partnership Opportunities to Accelerate Your Microbiome Research Whilst emerging phase 3 data is set to ignite investment and uncover the reality of microbiome-based therapeutics, there remain analytical challenges and translational bottlenecks that the community must come together to overcome, to redefine biopharmaceutical treatment and diagnostic options. […]

Heart failure affects about 6.2 million people in the United States, with half of the patients having heart failure with preserved ejection fraction (HFpEF) and counting. Yet, there is no treatment for this form of the disease as HFpEF is a heterogeneous syndrome and, like other disease areas, this makes it difficult to develop effective […]

It is clear the world of TGF-β contains vast potential and excitement, in the past year alone we have seen great advances, clinical setbacks, and novel insights into the role of TGF-β. Over the last 12 months, we have seen so many highs and lows, including clinical updates from large pharma such as Novartis, Oncotelic […]

The 5th Annual PARP, ATR & DDR Inhibitors Summit is the one-of-a-kind industry-focused summit dedicated to bringing new and novel next-generation DDR therapeutics to the clinic and finding optimal treatment combinations to expand application in multiple cancer indications. This is the key in-person biopharma conference for any research team developing inhibitors of specific DDR targets, […]

Built with biopharmaceutical industry insights, this conference will bring together key opinion leaders from Europe and the rest of the world to delve deep into the challenges associated with successfully designing and developing the next-generation of mRNA-based vaccines & therapeutics with improved specificity, delivery & efficacy for immuno-oncology, infectious diseases and beyond. With 20+ pioneering […]

Returning for its fifth year, the Antigen-Specific Immune Tolerance Summit will lean into the industry’s key challenges of understanding the mechanisms inducing tolerance, characterizing driver antigens of disease, monitoring immune response, and accelerating durable therapies into the clinic. This is your comprehensive guide to define your drug development strategy for 2022 and delve into the therapeutic opportunity […]

SMi Group’s 13th Annual Conference: RNA Therapeutics 2022 9th – 10th February 2022 Virtual Conference: Online Access Only www.therapeutics-rna.com Sponsored by: BIA Separations | eTheRNA Immunotherapies | Thermo Fisher Scientific Bolstering the latest advances and opportunities in RNA-based medicine The RNA therapeutics industry has grown at an exponential rate in recent years, with an increased spotlight following the industry’s leading […]

SMi’s 5th Annual 3D Cell Culture Conference Virtual Conference: Online Access Only 9-10 February 2022 http://www.3d-cellculture.com/ Sponsored by: CELLINK, CelVivo, Promega and Newcells BiotechDeveloping Complex, Translatable and Physiologically-Relevant Cellular Models in vitro Conference Co-Chairs: Stefan Przyborski, Professor of Cell Technology, Durham University and Philip Hewitt, Global Head of Early Investigative Toxicology, Merck 3D Cell Culture is […]

From Translation to Market-Entry: Advance Formulation, Clinical Development, & Commercialization of Phage-Based Therapies at the 4th Bacteriophage Therapy Summit 2022. Returning for its 4th year, the Bacteriophage Therapy Summit remains the only industry-focused forum dedicated to facilitating the discovery, translation & acceleration of bacteriophage research into targeted therapeutics with clinically significant results. View the full […]

This 2nd Operationalize: Expanded Access Programs summit is here to bring you solutions. By bringing together the world’s leading Expanded Access Programs thinkers, this exclusive platform will clarify the complex issues through end-to-end Managed Access/Compassionate Use program operationalization. Through open discussion, sharing best-practice case studies, and removing hypotheticals: this event provides an unrivaled opportunity to solve your challenges across […]

LEAP HR: Life Sciences Europe is your best opportunity to uncover the brand-new HR thinking that will enable you to tackle an ongoing talent shortage, and create the differentiated people strategies and organisational agendas you need to thrive in a hybrid life sciences operating environment. Step inside 20+ case studies of how biopharma organisations of all sizes are […]

The Only Global RAS Dedicated Conference is Returning in 2022 with the 3rd RAS/MAPK Pathway Targeted Drug Discovery Summit! Year on year, we are proud to unite the leading frontiers of the RAS industry to showcase expertise, technical data and pipeline updates, all geared toward accelerating the discovery and development of anti-RAS therapies. This February […]

As the CAR-T field continues to explode with new companies, investment, and clinical collaborations, it's more important than ever to stay ahead of the curve. Stakeholders across oncology are now turning to next generation developments and innovations to create the therapies of tomorrow. That’s why CAR-TCR Europe has evolved into the Next Generation CAR-TCR Summit: your […]

We are happy to announce that the Mitochondria-Targeted Drug Development Summit, focused on the pursuit for novel effective therapies for mitochondrial disorders/dysfunction, will be delivered in-person, for its 2nd edition. Mitobridge/Astellas, Minovia Therapeutics, Abliva, GenSight Biologics, Stealth Biotherapeutics and many more will unite drive to better understand how to create effective and scalable mitochondrial therapies. […]

As SGLT2 inhibitors redefine standard of care, opportunities to establish efficacy with surrogate endpoints take a step forward, and molecular phenotyping of disease etiology enables reclassification of patients to clinically actionable subtypes; drug development for chronic kidney disease has never been more exciting. The 4th Chronic Kidney Disease Drug Development Summit is your only industry-led event dedicated […]

The FDA’s recent approval of Welireg has sparked reinvigorated confidence in the field of Transcription Factor-therapeutics and as an increasing number of drug candidates are entering preclinical and clinical programs, this is a vital moment for the field. For the first time, you can join leaders from BMS, Scorpion Therapeutics, Ikena Oncology, Kronos Bio and […]

SMi’s 3rd Annual AI in Drug Discovery Conference Conference: 14 – 15 March 2022 London, UK Website: http://www.ai-indrugdiscovery.com/PJwl Chaired by Darren Green, Director of Computational Chemistry, GSK Sponsored by: Optibrium Exploring the Impact of Machine Learning and Artificial Intelligence in Drug Development from Discovery to Healthcare SMi Group is proud to present its 3rd Annual AI in […]

2021 marked a successful year for the protein degradation field with several candidates entering the clinic. As the European centric targeted protein degradation landscape matures and the number of pre-clinical candidates expected to enter clinical development in the next year grows ever more, the 2nd TPD Europe Summit returns, in person, to highlight key challenges […]

SMi’s 16th Annual Conference Parallel Trade 21-22 March, 2022 | Conference http://parallel-trade.com/pharmajournalistwl NAVIGATING THE CHALLENGES AND LEGAL LANDSCAPES OF PARALLEL TRADE SMi presents its 16th annual Parallel Trade conference on the 21st and the 22nd March 2022. As the only parallel trade conference in Europe, this event provides the perfect platform for industry experts from […]

The inaugural GPCRs - Targeted Drug Discovery Summit has been established to tap into new drug discovery opportunities in undrugged and orphaned GPCRs by better understanding the complex signaling GPCR pathway, leveraging new structural and genetic data as well as, emerging screening tools and technologies and up and coming modalities. Discover data driven case studies […]

The 3rd STING & TLR-Targeting Therapies Summit is coming at a timely inflection point in this field. With multiple TLR agonists moving into the clinic, STING agonists exposing new challenges, multiple approvals on the horizon, and more novel targets & combinations currently undergoing exciting pre-clinical validation than ever before, this unique and highly anticipated industry-focused […]

In the context of intense scrutiny over the safety and durability of blood disease-targeted gene therapies and a flurry of excitement around novel gene editing technologies, the 3rd Gene Therapy for Blood Disorders Summit will unite the leading large pharma and innovative biotechs to share essential learnings from across this rapidly evolving field, enabling you […]

12th Annual World ADC London 29th March - 1st April 2022 London The ADC field is going from strength to strength, further catalysed in 2021 by the approvals of Zynlonta and Tivdak respectively, bringing the total number of commercially available ADCs to 11. Returning in-person in from 29th March – 1st April, be part of the 12th Annual World ADC […]

Celebrating 20 years of FDA approval and high efficacy profiles, kinase inhibitors have changed the face of oncology treatment. However, increasing resistance and safety issues limit the success of existing kinase inhibitor classes. The inaugural Next Generation Kinase Inhibitors Summit is the only industry-focused meeting dedicated to applying novel kinase biology to drug development and […]

2021 was a game-changing year for the NK cell community. Positive clinical results have forced the field to wake up to the potential of these pioneering approaches. Supporting the field since its’ infancy, the Innate Killer Summit returns for its 7th year as the leading, industry-defining forum dedicated to advancing the field to achieve clinical success. Spanning the current […]

Mitigating Toxicity & Revolutionizing Muscle Targeting The 2nd Gene Therapy for Muscular Disorders Summit will be returning as an in-person event to Boston in April 2022, to help gene therapy developers targeting muscular disorders to overcome safety and toxicity challenges and effectively translate their programs into the clinic. Highlighting AAV and gene editing challenges for […]

Accelerating the Development of Novel Anti-VEGF, VEGF-independent Therapies & Drug Delivery Options To Reduce Clinical Burden, Widen Therapeutic Index & Treatment Options for Non-responders The second edition of the industry-led Wet AMD & DME Drug Development Summit will give comprehensive insight into the current and emerging angiogenesis-, inflammatory-directed and anti-fibrotic drug development programmes for these […]

PURIFY Conclaves are pioneers of dedicated conferences in India that will help stretch possibilities, be it discovery, development or scaleups! The pharmaceutical industry continues to dwell deeper into the growing possibilities for chromatography purification; the PURIFY conclaves touches upon diverse aspects of chromatography purification. The attendees at PURIFY get exposed to a myriad of topics […]